nvc-422 has been researched along with retapamulin* in 1 studies
1 other study(ies) available for nvc-422 and retapamulin
| Article | Year |
|---|---|
No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli.
Twenty-five serial passages of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and 50 passages of methicillin-resistant Staphylococcus aureus resulted in no significant increase in NVC-422 MICs, while ciprofloxacin MICs increased 256-fold for E. coli and 32-fold for P. aeruginosa and S. aureus. Mupirocin, fusidic acid, and retapamulin MICs for MRSA increased 64-, 256-, and 16-fold, respectively. No cross-resistance to NVC-422 was observed with mupirocin-, fusidic acid-, and retapamulin-resistant strains. Topics: Anti-Bacterial Agents; Bridged Bicyclo Compounds, Heterocyclic; Ciprofloxacin; Diterpenes; Drug Resistance, Multiple, Bacterial; Escherichia coli; Fusidic Acid; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mupirocin; Pseudomonas aeruginosa; Staphylococcus aureus; Taurine | 2012 |